Professional Position: Retired Vice President, Patient Advocacy
Company: Travere Therapeutics
Location: Egg Harbor Township, NJ

Eve has been passionately advocating for equitable access and quicker diagnoses and treatment of rare and debilitating diseases throughout her 25 years as a patient advocate. She has embraced the knowledge that true progress will not happen overnight – this requires a community steadfast in their shared commitment.

Eve has also walked in the shoes of many ALS community members, having supported her dear friend, Eileen Marcus, as a caregiver throughout her four-year battle with ALS.

Eve spent ten years as a biotechnology industry leader in patient advocacy, working initially with Lexicon Pharmaceuticals and then with Travere Therapeutics. At both companies, she championed the development of a robust focus on building and supporting patient diversity and inclusion initiatives, both internally and externally. She worked together with the Black Women’s Health Imperative to launch the Rare Disease Diversity Coalition in 2020.

While at Travere, she created a Rare Disease Patient Advisory Council (RDPAC), consisting of 20 lay patients/caregivers, representing multiple therapeutic categories. RDPAC members provide unmet needs insights to the clinical research team and others across the company and help ensure clinical trials are designed reflecting patient and caregiver input.

Eve has expertise in therapeutic and other categories including Health Policy, Health Equity and Inclusion, Issues & Crisis Management, Multicultural Communications, Patient Centricity, Senior and Women’s Health, Nephrology, Oncology (Breast Cancer & Neuroendocrine Tumors), Neurology and Mental Health.

She spent 12 years as founder and partner in a Philadelphia-based healthcare Public Relations agency, Vox Medica, with clients including AstraZeneca, GlaxoSmithKline, Janssen and Eisai. Eve was spotlighted in the PharmaVoice ”100 of the Industry’s Most Inspiring People” on three separate occasions and honored as the Healthcare Businesswomen’s Association STAR of the Year in 2014. She has also been nominated by Global Genes as a 2024 RARE Champion for Health Equity.

In addition to her appointment to the ALS Association Board of Trustees, she also serves on the board of NephCure (the leading rare kidney disease patient organization) and for 8 years she has served on the board of Sisters Network Inc.